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Abstract
Introduction The inhaled corticosteroid (ICS) fluticasone
furoate is in development, in combination with the long-
acting beta2-agonist vilanterol for the once-daily treatment
of asthma and chronic obstructive pulmonary disease and
as a monotherapy treatment for asthma. Corticosteroids,
including ICSs, have the potential to induce dose-depen-
dent systemic effects on the hypothalamic–pituitary–adre-
nal (HPA) axis. Cortisol suppression has been observed in
asthma patients with normal HPA axis function at baseline
on receiving high doses of ICSs, and is associated with
adverse effects on a number of physiological processes.
The measurement of 24-h serum cortisol and 24-h urinary
cortisol excretion are sensitive methods for assessing
adrenocortical activity, and can evaluate cortisol suppres-
sion in a dose-dependent manner.
Objective The purpose of the meta-analysis presented
here was to characterize the population pharmacokinetic/
pharmacodynamic relationship between fluticasone furoate
systemic exposure [as measured by area under the con-
centration–time curve over 24 h postdose (AUC24)] and
both 24-h weighted mean serum cortisol (WM24) and 24-h
urine cortisol excretion in healthy subjects and subjects
with asthma.
Methods The serum cortisol meta-analysis integrated
eight studies; five Phase I studies in healthy subjects, two
Phase IIa studies, and one Phase III study in subjects with
asthma. Each study included serial blood sampling for
estimation of WM24. The urine cortisol meta-analysis
integrated three studies: one Phase I study in healthy
subjects, and one Phase IIb and one Phase III study in
subjects with asthma. Each study included complete 0–24 h
urine collection for estimation of urine cortisol excretion.
All studies included blood sampling for estimation of flu-
ticasone furoate AUC24. A sigmoid maximum effect (Emax)
model was fitted to fluticasone furoate AUC24 and serum
cortisol and urine cortisol data using nonlinear mixed-
effect modeling with the computer program NONMEM.
Results Over a wide range of systemic fluticasone furoate
exposure representing the therapeutic and supratherapeutic
range, the relationship between fluticasone furoate AUC24
and WM24 and 24-h urine cortisol excretion was well
described by an Emax model. The average estimate of AUC
producing 50 % of maximum effect (AUC50) was similar
for the serum cortisol and urine cortisol models with values
of 1,556 and 1,686 pgh/mL, respectively. Although for-
mulation/inhaler was shown to be a significant covariate on
the estimates of both WM24 at zero concentration (C0) and
AUC50 in the serum cortisol model, the differences were
small and believed to be due to study variability. Age was
shown to be a significant covariate on the estimates of both
C0 and AUC50 in the urine cortisol model, and was con-
sidered to be a reflection of lower urine cortisol excretion
in adolescents.
Conclusion A pharmacokinetic/pharmacodynamic model
has been established over a wide range of systemic fluti-
casone furoate exposure representing the therapeutic and
supratherapeutic range to both WM24 and 24-h urine
cortisol excretion. The values of AUC50 of 1,556 and
1,686 pgh/mL, respectively, are several times higher than
average fluticasone furoate AUC24 values observed at
clinical doses of fluticasone furoate (B200 lg). The models
predict a fluticasone furoate AUC24 of 1,000 pgh/mL
would be required to reduce 24-h serum cortisol or 24-h
urine cortisol excretion by 20 and 17 %, respectively.
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1 Introduction
The inhaled corticosteroid (ICS) fluticasone furoate (FF;
GW685698) is in development, in combination with the
long-acting beta2-agonist (LABA) vilanterol (VI;
GW642444M) for once-daily treatment of asthma and
chronic obstructive pulmonary disease (COPD). Flutica-
sone furoate is also being developed as a monotherapy
treatment for asthma. The pharmacokinetic, pharmacody-
namic, and safety profiles of the fluticasone furoate/vilan-
terol combination have been described in healthy subjects
as well as in patients with asthma and COPD [1–4]. In
addition, once-daily administration of fluticasone furoate/
vilanterol was effective at improving lung function in
patients with COPD [5, 6] or asthma [7, 8].
Endogenous cortisol is responsible for several important
functions within the body and its level is regulated by a
feedback system, involving the hypothalamus, pituitary,
and adrenal glands, known as the HPA axis. Corticoste-
roids, including ICS, have the potential to induce dose-
dependent systemic effects on the HPA axis [9–11]. High
doses of ICSs have resulted in cortisol suppression in
asthma patients with normal HPA axis function at baseline
[12, 13] and this finding is associated with adverse effects
on a number of physiological processes [14, 15]. Moni-
toring systemic cortisol levels is one of the most sensitive
markers of HPA suppression and the measurement of 24-h
serum cortisol (serum cortisol) is a sensitive method for
assessing adrenocortical activity, and can evaluate cortisol
suppression in a dose-dependent manner [11]. However,
this method requires that serial blood samples are collected
over a 24-h period and this is not always feasible in a large
clinical trial setting. An acceptable alternative is the use of
complete 24-h urine collection for evaluation of cortisol
excretion [11].
Although there is extensive data in the literature on
other ICSs [11], no data has yet been published for fluti-
casone furoate characterizing the systemic exposure rela-
tionship with reductions in either serum cortisol or urinary
cortisol. The purpose of the meta-analysis presented here
was to characterize the population pharmacokinetic/phar-
macodynamic relationship between fluticasone furoate
systemic exposure [as measured by 24-h area under the
concentration–time curve (AUC24)] and 24-h weighted
mean serum cortisol (WM24) and also a relationship
between fluticasone furoate systemic exposure (AUC24)
and 24-h urine cortisol excretion in healthy subjects and in
subjects with asthma.
The studies included in the meta-analyses allowed
investigation of the fluticasone furoate AUC24 versus
cortisol relationship over a wide concentration range, as
well as assessment of the influence of population (healthy
subjects or patients with asthma), formulation/inhaler
[ROTADISK/lactose, DISKUS/cellobiose octaacetate
(COA) ? lactose or dry powder inhaler (DPI)/lactose] on
any pharmacokinetic/pharmacodynamic relationship. RO-
TADISK and DISKUS (GlaxoSmithKline, UK) included
doses up to ten times and eight times greater than the
maximum proposed fluticasone furoate therapeutic dose
of 200 lg, whilst for DPI the maximum dose was only
four times greater. Most of the repeat dose studies con-
ducted with fluticasone furoate/vilanterol administered via
the DPI utilized doses of fluticasone furoate that had no
detectable effect on cortisol [16]. In dose ranging studies,
fluticasone furoate (doses ranging from 25 to 800 lg) did
not significantly suppress 24-h urine cortisol excretion
after 8 weeks once-daily dosing relative to placebo, with
the exception of the 800-lg dose that served to define a
supratherapeutic dose [16]. To enable characterization of
the relationship between fluticasone furoate AUC24 and
cortisol, it was necessary to include studies where su-
pratherapeutic doses up to 2,000 lg (representing ten
times higher than the maximum clinical dose) were used,
which resulted in significant suppression of cortisol pro-
duction. Many of these studies were conducted in early
development and utilized other formulations and/or
inhalers.
2 Methods
The meta-analysis for the serum cortisol analysis inte-
grated eight studies; five Phase I studies (Studies 1–5) in
healthy subjects, two Phase IIa studies in subjects with
asthma (Studies 6 and 7), and one Phase III study in
subjects with asthma (Study 9). Each of these studies
included blood sampling for estimation of AUC24 and
serial blood sampling for estimation of WM24 as detailed
in Table 1.
The meta-analysis for the urine cortisol analysis inte-
grated three studies: one Phase I study in healthy subjects
(Study 5), one Phase IIb study in subjects with asthma
(Study 8), and one Phase III study (Study 9). Each of these
studies included blood sampling for estimation of flutica-
sone furoate AUC and complete 24-h urine collection for
estimation of 24-h urine cortisol excretion as detailed in
Table 1.
The studies used in these meta-analyses used the DPI as
well as formulations administered via ROTADISK or
DISKUS. It is possible that these different formulations/
inhalers may not have delivered the same lung dose.
Because the pharmacokinetic/pharmacodynamic analysis
involves the observed systemic exposure, and is related to
systemic effects, differences in delivered lung dose have no
relevance for these analyses and therefore pooling of data






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































All trials were conducted in compliance with Good
Clinical Practice with the ethical principles that have their
origins in the Declaration of Helsinki. The investigators
obtained Institutional Review Board approvals for the
study protocols. All subjects gave their written informed
consent before participating in the trial.
Venous blood samples for analysis of plasma flutica-
sone furoate concentrations were collected in KEDTA
tubes at the times detailed in Table 1. The blood samples
were put on ice until centrifugation at 1,500 g for
approximately 10 min at 4 C. The plasma was trans-
ferred into polypropylene containers and frozen at
approximately -20 C.
2.1 Bioanalytical Methods
Plasma samples were analyzed for fluticasone furoate,
using either [13C2H3]GW685698 or [
13C3]CCI18781 as
internal standard, by solid-phase extraction followed by
high-performance liquid chromatography–tandem mass
spectrometry (HPLC–MS/MS) using a Perkin Elmer Sciex
API 3000. A gradient system using ammonium formate
pH 5.0 buffer (26:74, v/v with methanol) and methanol
was run with a Phenomex Prodigy ODS3 column
(150 9 2.0 mm i.d., 5 lm particle size) at 40 C. The ion
transition for fluticasone furoate was m/z 539–313. The
validation range of the assay was 10–2,000 pg/mL. Where
reported concentrations were above the higher limit of
quantification, the plasma samples were diluted, as appro-
priate, to provide concentrations within the validated range.
Interbatch precision (coefficient of variation; CV) was
B8.2 % over the assay range; the lower limit of quantifi-
cation for fluticasone furoate was 10 pg/mL. Quality con-
trols prepared at three different concentrations were
analyzed with each batch of samples against separately
prepared calibration standards to assess the day-to-day
performance of the assay. Quality control results from this
study met the acceptance criteria of no more than one third
of the quality control results deviating from the nominal
concentration by more than 15 %, with at least one quality
control result acceptable at each concentration.
2.2 Pharmacokinetic Analysis
Fluticasone furoate concentration–time data were subjected
to noncompartmental analysis using WinNonlin Pro v2.1
(Pharsight Corporation, Mountain View, CA, USA) or
higher to generate estimates of AUC24. The linear trape-
zoidal rule was used for intervals where the concentration
data was increasing and the logarithmic trapezoidal rule
was used for intervals where the concentration data was
decreasing.
2.3 Pharmacodynamic Assessments
2.3.1 Serum Cortisol Population
The serum cortisol population consisted of all subjects who
did not have protocol violations that were considered to
affect the serum cortisol endpoint and whose serum sam-
ples were not considered to have confounding factors that
would affect the interpretation of the results. Reasons for
exclusion from the serum cortisol population included:
• two or more consecutive missing cortisol concentra-
tions over a 24-h collection period. Note: concentra-
tions below the assay’s lower limit of quantification
were considered nonmissing values for serum cortisol,
• used a protocol-prohibited systemic, oral, or depot
corticosteroid during the study,
• used a protocol-prohibited ICS during the study,
• used a protocol-prohibited intranasal corticosteroid
during the study,
• used a protocol-prohibited potent cytochrome P450
(CYP) 3A4 inhibitor during the study.
2.3.2 Urine Cortisol Population
The urine cortisol population consisted of all subjects who
did not have protocol violations that were considered to
affect the urine cortisol endpoint and whose urine samples
were not considered to have confounding factors that
would affect the interpretation of the results. Subjects were
excluded from the urine cortisol population prior to
breaking the blind. Reasons for exclusion from the urine
cortisol population included:
• urine volumes (0–24 h) of \600 mL (women) or
\800 mL (men),
• 24-h creatinine excretion below the lower limit of
threshold range (where the threshold range is defined as
the mean ± 2.5 standard deviations of the observed
data),
• collection time intervals outside 24 ± 2 h,
• used any corticosteroid in violation of the protocol,
• used a protocol-prohibited potent CYP3A4 inhibitor
during the study.
The 24-h serum cortisol weighted mean (AUC24/24 h)
was derived by dividing the AUC (calculated using the
linear trapezoidal rule) by the sample collection time
interval. The sample collection time interval is defined as
the difference between the time of the last cortisol sample
and the time of the first cortisol sample. The AUC was
calculated from the first nonmissing time points to the last
nonmissing time points. Concentrations below the assay’s
lower limit of quantification were considered nonmissing
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and were set to half the lower limit of quantification when
deriving the weighted mean and AUC. If an observation
was missing between two nonmissing observations, the




Population modeling of pharmacokinetic/pharmacody-
namic data was performed using nonlinear mixed effect
modeling with the computer program NONMEM v7
(ICON plc, US) running in the predictive modeling envi-
ronment, a UNIX server-based environment for NON-
MEM analysis. The method selected for minimization
was first-order conditional estimation method with inter-
action [18]. Supporting application interfaces for data
handling, exploratory diagnostics, simulation, and graphi-
cal representation of the data included Xpose V4 [19], R
(The R Foundation for Statistical Computing Version
2.13.1), PsN, and Excel 2007.
Previous analyses have shown the relationships for flu-
ticasone furoate AUC24 and WM24 and for fluticasone
furoate AUC24 and 24-h urine cortisol excretion to be
described by a sigmoid Emax model (GlaxoSmithKline,
unpublished data, Study FFA10002 and FFA103096).
Steady-state fluticasone furoate AUC24 values covered a
wide range across the studies included in the pharmaco-
kinetic/pharmacodynamic meta-analyses; from noncalcu-
lable due to values below the lower limit of quantification
(assigned as zero for the analysis) to [6,300 pgh/mL. At
the high fluticasone furoate AUC values, some serum
cortisol concentrations were reported as nonquantifiable.
These nonquantifiable serum cortisol values were set to
half the lower limit of quantification for estimation of the
WM24. Nonquantifiable urine cortisol concentrations were
observed at the high fluticasone furoate AUC values.
However, it was not possible to apply an imputation to
these records and hence urine cortisol excretion for these
cases has been set to missing for the analysis.
Both single-dose and repeat-dose data were available for
serum cortisol and therefore a sigmoid Emax model, with
different slopes for single and repeat doses, was fitted to
fluticasone furoate AUC24 and WM24 data using NON-
MEM (Eqs. 1, 2).





Emax ¼ C0  expðk  DayÞ ð2Þ
where Emax is the WM24 value at maximum effect, C0 is
the WM24 at zero concentration, AUC50 is the AUC
producing 50 % of maximum effect, c is the Hill coeffi-
cient, and k is the coefficient on number of days of dosing.
Only repeat-dose data were included for the 24-h urinary
cortisol excretion analysis. The following sigmoid Emax
model was fitted to fluticasone furoate AUC24 and 24-h
urine cortisol data using NONMEM (Eq. 3).





where Emax is the urine cortisol at the maximum effect, C0
is the urine cortisol at zero concentration, AUC50 is the
AUC producing 50 % of maximum effect, and c is the Hill
coefficient.
The stepwise covariate model (SCM) building tool of
PsN was used to investigate factors that may impact the
model parameters, including subject demographic charac-
teristics (sex, age, and weight), formulation/inhaler (fluti-
casone furoate blended with lactose administered via
ROTADISK or administered via DPI, or fluticasone furoate
blended with lactose and COA administered via DISKUS/
ACCUHALER), and population (healthy subjects or sub-
jects with asthma). This procedure implements forward
selection with criteria of p = 0.05 followed by backward
elimination model selection with criteria of p = 0.01. Race
was to be evaluated, but because 94 % of the serum cor-
tisol population and 85 % of the urine cortisol population
were white, it was not deemed appropriate.
Model evaluation to assess the adequacy of the final
models, including the effects of statistically significant
covariates, was performed using a visual predictive check
procedure [20]. This procedure was conducted as follows:
1,000 replicates of the original dataset were simulated,
based on the parameter estimates of the final model, and a
95 % prediction interval computed based on the simulated
datasets. The observed fluticasone furoate AUC24 versus
cortisol data were plotted on the prediction interval to




A summary of subject demographic characteristics for
subjects who provided data for the serum cortisol and urine
cortisol analyses are presented in Table 2. The majority of
data (61.0 and 93.1 %, respectively) were provided by
subjects with asthma. Data from 372 subjects providing
752 observations were included in the final analysis for
serum cortisol, and from 597 subjects providing 682
observations in the final analysis for urine cortisol.
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3.2 Relationship Between Fluticasone Furoate AUC24
and 24-h Weighted Mean Serum Cortisol
A sigmoid Emax model, with different slopes for single and
repeat doses, was fitted to fluticasone furoate AUC24 and
WM24 data using NONMEM. The population parameter
estimates for the base model are presented in Table 3.
Differences between population and individual estimates
were partially explained by interindividual variability on
AUC50 and C0.
The serum cortisol base model was subjected to SCM
building assessing the potential for population type (heal-
thy subjects or subjects with asthma), age, weight, sex, and
formulation/inhaler (FOIH) to affect C0 or AUC50. The
factors of population (healthy subjects or subjects with
asthma), age, weight, and sex were not identified as sig-
nificant covariates from the SCM building. The population
parameter estimates for the final model are presented in
Table 4. The goodness-of-fit plot for the final model shows
that the final model appears to provide a reasonable pre-
diction of the serum cortisol relationship (Fig. 1).
Although FOIH was shown to be a significant covariate
(p \ 0.05) on the estimate of C0, the median values and
ranges for C0 for each FOIH variation were very similar.
FOIH was also shown to be a significant covariate on the
estimate of AUC50. In the model, ROTADISK provided the
greatest number of records (62 %) and hence was the ref-
erence formulation. It should be noted that subjects using
DISKUS only constituted 16 % of the overall serum cor-
tisol population. Although the median values of AUC50
were higher for DISKUS and lower for DPI compared with
Table 2 Summary of subject demographic characteristics for the
serum cortisol and urine cortisol pharmacokinetic/pharmacodynamic
populations
Total number of subjects Serum cortisol Urine cortisol
Included in meta-analysis, n 372 597
Population
Healthy subjects, n (%) 145 (39.0) 41 (6.9)
Subjects with asthma, n (%) 227 (61.0) 556 (93.1)
Demographics—total (healthy subjects and asthma)
Age (years), median (range) 31 (12–65) 44 (12–75)
Sex, n (%)
Female 88 (23.7) 243 (40.7)
Male 284 (76.3) 354 (59.3)
Height (cm), median (range) 175.0 (145–200) 168.0 (135–194)







350 (94) 508 (85)
African American/African
heritage
12 (3) 19 (3)
Asian–East Asian heritage 1 (\1) 0
Asian–Central/South Asian
heritage
1 (\1) 8 (1)
Asian–Japanese heritage 2 (\1) 1 (\1)
Asian–South East Asian heritage 0 18 (3)
American Indian/Native Alaskan 1 (\1) 20 (3)
White–Arabic/North African 1 (\1) 3 (\1)
Other 4 (1) 20 (3)
Table 3 Parameter estimates from base model for fluticasone furo-
ate AUC and serum cortisol
Parameter Estimate (95 % CI) RSE (%)
C0 (nmol/L) 215 (209–221) 0.304
AUC50 (pgh/mL) 1,845 (1,652–2,060) 0.763
k 8.08 (4.71–13.87) 13.2
GAM SD 0.955 (0.767–1.140) 10.0
GAM RD 3.02 (2.29–3.75) 12.4
C0 variability 22.8 (19.7–25.3) 12.3
AUC50 variability 34.2 (23.9–42.1) 26.2
Proportional error 15.8 (11.8–19.0) 22.3
Additive error (nmol/L) 16.5 (3.5–23.1) 48.7
AUC50 the FF area under the concentration–time curve over 24 h
(AUC24) producing 50 % of maximum effect, C0 the 24-h weighted
mean at zero FF AUC24, CI confidence interval, FF fluticasone
furoate, GAM the slope for single dose and repeat dose, k coefficient
on the number of days of dosing, RD repeat dose, RSE relative
standard error, SD single dose
Table 4 Parameter estimates from final model for fluticasone furo-
ate AUC and serum cortisol
Parameter Estimate (95 % CI) RSE (%)
C0 (nmol/L) 221 (213 to 230) 0.404
AUC50 (pgh/mL) 1,556 (1,380 to 1,755) 0.829
k 7.39 (3.42 to 15.96) 19.7
GAM SD 0.915 (0.648 to 1.180) 14.9
GAM RD 3.03 (2.50 to 3.56) 8.91
FOIH (DISKUS) on AUC50 -0.166 (-0.438 to 0.106) -83.7
FOIH (DPI) on AUC50 0.490 (0.255 to 0.755) 27.6
FOIH (DISKUS) on C0 -0.0783 (-0.017 to 0.140) -40.1
FOIH (DPI) on C0 0.157 (0.070 to 0.244) 28.3
C0 variability 21.4 (18.4 to 23.9) 12.8
AUC50 variability 27.9 (18.4 to 34.9) 28.9
Proportional error 16.0 (11.8 to 19.2) 23.2
Additive error (nmol/L) 15.8 (4.11 to 21.98) 47.6
AUC50 the FF area under the concentration–time curve over 24 h
(AUC24) producing 50 % of maximum effect, C0 the weighted mean
24 at zero FF AUC24, CI confidence interval, DPI dry powder inhaler,
FF fluticasone furoate, FOIH formulation/inhaled, GAM slope for
single dose and repeat dose, k coefficient on the number of days of
dosing, RD repeat dose, RSE relative standard error, SD single dose
Fluticasone Furoate and Cortisol Suppression 891
the median AUC50 values for the ROTADISK, the majority
of values were within the range of AUC50 values estimated
for ROTADISK.
The plot for the visual predictive check for the flutica-
sone furoate AUC24–24-h serum cortisol model (Fig. 2)
showed that the majority of the data were captured in the
prediction interval encompassing 95 % of the population as
indicated by the 2.5 and 97.5 percentile boundaries indi-
cating that the model was valid for this dataset.
3.3 Relationship Between Fluticasone Furoate AUC24
and 24-h Urinary Cortisol Excretion
A sigmoid Emax model was also fitted to fluticasone furoate
AUC24 and 24-h urine cortisol excretion data using
NONMEM and the population parameter estimates for
the final model are presented in Table 5. Due to the greater
variability of the urine cortisol excretion data compared
with serum cortisol data it was necessary to fix the slope
parameter. Initially the estimate from the serum cortisol
model was used (3.06) in the modeling procedure, but
covariance could not be obtained with this value, and a
value of 3.20 was chosen following evaluation of different
estimates.
The urine cortisol base model was subjected to SCM
building to assess the potential for population (healthy
subjects and subjects with asthma), age, weight, sex, and
FOIH to affect C0 and AUC50. The factors of population
(healthy subjects or subjects with asthma), FOIH, weight,
and sex were not significant covariates from the SCM
building. The results showed only age to have significant
impact on the estimates of both C0 and AUC50. Differences
between population and individual estimates were partially
explained by interindividual variability (g) on AUC50 and
C0. Due to the paucity of data near Emax this parameter was
Fig. 1 Diagnostic plots for the final serum cortisol model. Solid lines represent the line of identity or the ordinate value of zero; dashed lines
represent a Loess smoother. AUC24 area under the concentration–time curve over 24 h postdose, FF fluticasone furoate
Fig. 2 Visual predictive check for serum cortisol final model. Solid
red line is the 50th percentile of the observed data and the dashed
lines the 5th and 95th percentiles of the observed data. The shaded
areas are the 95 % confidence intervals for the simulated 5th, 50th,
and 95th percentiles. AUC24 area under the concentration–time curve
over 24 h postdose, FF fluticasone furoate
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not well estimated as reflected by the RSE of 58.1 %. The
population parameter estimates for the final model are
presented in Table 6. The goodness-of-fit plots for the final
model shows that the final model appears to provide a
reasonable prediction of the urine cortisol relationship
(Fig. 3).
There was considerable variability in the observed data
for 24-h urine cortisol excretion and although age was
shown to be a significant covariate based on SCM and
objective function there was no obvious improvement in
the goodness-of-fit plots or in the estimate of residual
variability (Table 5 vs. Table 6).
The plot for the visual predictive check for the flutica-
sone furoate AUC24–24-h urine cortisol model (Fig. 4)
showed that the majority of the data were captured within
the prediction interval that encompassed 95 % of the
population as indicated by the 2.5 and 97.5 percentile
boundary indicating that the model was valid for this
dataset.
4 Discussion
Over a wide range of systemic fluticasone furoate exposure
representing the therapeutic and supratherapeutic range, the
relationship between fluticasone furoate AUC24 and both
WM24 and 24-h urine cortisol excretion was well descri-
bed by an Emax model. The average estimate of AUC50
was similar for both the serum cortisol and urine corti-
sol models with values of 1,556 pgh/mL (95 % CI
1,380–1,755) and 1,686 pgh/mL (95 % CI 1,480–1,920),
respectively. These AUC50 values are notably higher than
average fluticasone furoate AUC24 values observed at
clinical doses of fluticasone furoate (B200 lg; mean
AUC24 of 495 pgh/mL for subjects with asthma
administered fluticasone furoate/vilanterol 200/25 lg;
GlaxoSmithKline unpublished data, 2012). Based on the
models, a fluticasone furoate AUC24 of 1,000 pgh/mL
would be required to reduce 24-h serum cortisol or 24-h
urine cortisol excretion by 20 and 17 %, respectively. For
the serum Emax model, there were different slopes for the
single-dose and repeat-dose data. From the results of this
model, it can be seen that the same fluticasone furoate
AUC24 obtained following repeat dosing results in a greater
suppression of serum cortisol, compared with the level of
suppression observed after a single exposure. This is an
expected finding because serum cortisol measured after a
single dose includes cortisol produced prior to dosing and
does not reflect the true magnitude of cortisol suppression
produced under steady-state conditions. Maximum effect
can be observed after 3–4 days of dosing once fluticasone
furoate steady state is achieved. Although the median
values and ranges for C0 for each FOIH were very similar,
FOIH was shown to be a significant covariate on the esti-
mates of C0. This may be a spurious finding because C0 is
the cortisol level at zero concentration, and hence impact
by FOIH is implausible. Therefore, this finding is likely
just a reflection of study-to-study variability. FOIH was
also shown to be a significant covariate on the estimate of
AUC50. As with C0, this finding may also be a reflection of
study-to-study variability. Also of note, for studies used in
the serum cortisol analysis, ROTADISK and DISKUS
administration included doses up to ten times and eight
times greater than the maximum fluticasone furoate ther-
apeutic dose of 200 lg, whilst for DPI the maximum dose
was equivalent. Hence, for DPI the full effect on serum
cortisol would not have been observed and may have
impacted the estimate of AUC50.
Table 5 Parameter estimates from base model for fluticasone
furoate AUC and urine cortisol
Parameter Estimate (95 % CI) RSE (%)
C0 (mg) 23.1 (21.5–24.8) 1.16
AUC50 (pgh/mL) 1,588 (1,380–1,826) 0.963
Emax (mg) 0.98 (-0.549–2.51) 79.6
GAM 3.20 fixed
C0 variability 65.3 (58.3–71.6) 10.3
AUC50 variability 40.5 (22.8–52.5) 34.8
Proportional error 26.0 (21.7–29.7) 15.6
Additive error (mg) 2.21 (0.443–3.098) 49.0
AUC50 the area under the concentration–time curve producing 50 %
of maximum effect, C0 the 24 h urine cortisol excretion at zero
concentration, CI confidence interval, Emax the 24 urine cortisol
excretion at maximum effect, GAM slope for single dose and repeat
dose, RSE relative standard error
Table 6 Parameter estimates from final model for fluticasone furo-
ate AUC and urine cortisol
Parameter Estimate (95 % CI) RSE (%)
C0 (mg) 22.0 (20.5–23.6) 1.13
AUC50 (pgh/mL) 1,686 (1,480–1,920) 0.908
Emax (mg) 0.707 (-0.0990–1.510) 58.1
GAM 3.20 fixed
Age on AUC50 0.0104 (0.003–0.018) 35.7
Age on C0 -0.0141 (-0.018 to -0.010) -14.3
C0 variability 62.5 (51.9–71.6) 15.9
AUC50 variability 42.5 (29.3–52.5) 26.9
Proportional error 25.7 (18.7–31.1) 24.1
Additive error (mg) 2.03 (0.825–2.746) 42.6
AUC50 the area under the concentration–time curve producing 50 %
of maximum effect, C0 the 24 h urine cortisol excretion at zero
concentration, CI confidence interval, Emax the 24 h urine cortisol at
maximum effect, GAM slope for single dose and repeat dose, RSE
relative standard error
Fluticasone Furoate and Cortisol Suppression 893
For the relationship between fluticasone furoate AUC24
and 24-h urine cortisol excretion, age was shown to be a
significant covariate on the estimates of both C0 and
AUC50. There was considerable variability in the observed
data for 24-h urine cortisol excretion, and although age was
shown to be a significant covariate based on SCM and
objective function there was no obvious improvement in
the goodness-of-fit plots or in the estimate of residual
variability. This finding may in part be explained by the
lower underlying 24-h urine cortisol excretion in adoles-
cent subjects compared with adults reported in the litera-
ture [21]. In addition, age was not identified as a significant
covariate for the serum cortisol model and therefore the
relevance of age as a covariate on estimate of C0 and
AUC50 for the urine cortisol relationship is not clear and is
considered to be a reflection of lower urine cortisol
excretion in adolescents.
Although the analysis included data from a number of
studies, the analytical methodology for fluticasone furoate
analysis in plasma was very similar, sensitive, and selec-
tive, and included robust internal assay validation. This
was also the case for the analytical methods used for both
serum and urine cortisol where sensitive and selective
HPLC–MS assays were used for all studies. Therefore,
combining data from these studies for the pharmacokinetic/
pharmacodynamic analysis is not considered to have any
impact on the outcome.
Similar relationships have been described for other ICS,
notably an Emax model has been described for fluticasone
propionate [22], which estimated an AUC50 of approxi-
mately 2,000 pgh/mL (after adjustment for the difference
due the inadequate selectivity of the radioimmunoassay
used to analyze samples for fluticasone propionate in that
study compared with the more selective HPLC–MS assay
[23]). This would indicate that fluticasone furoate is 1.25
times more potent on reduction in cortisol compared with
Fig. 3 Diagnostic plots for the final urine cortisol model. Solid lines represent the line of identity or the ordinate value of zero; dashed lines
represent a Loess smoother. AUC24 area under the concentration–time curve over 24 h postdose, FF fluticasone furoate
Fig. 4 Visual predictive check for urine cortisol final model. Solid
red line is the 50th percentile of the observed data and dashed lines
are the 5th and 95th percentiles of the observed data. The shaded
areas are the 95 % confidence interval for the simulated 5th, 50th,
and 95th percentiles. AUC24 area under the concentration–time curve
over 24 h postdose, FF fluticasone furoate
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fluticasone propionate. However, to put into context of
relative therapeutic index, it should be noted that the daily
clinical dose of fluticasone furoate (100 or 200 lg) is five
times lower than that of fluticasone propionate (500 or
1,000 lg), and, therefore, the therapeutic index for fluti-
casone furoate with respect to cortisol reduction is no
worse than that for fluticasone propionate.
5 Conclusion
A pharmacokinetic/pharmacodynamic model has been
established over a wide range of systemic fluticasone
furoate exposure representing the therapeutic and supra-
therapeutic range to both 24-h weighted WM24 and 24-h
urine cortisol excretion. The values of AUC50 of 1,556 and
1,686 pgh/mL are notably higher than average fluticasone
furoate AUC24 values observed at clinical doses of fluti-
casone furoate (B200 lg). Based on the models, a fluti-
casone furoate AUC24 of 1,000 pgh/mL would be required
to reduce 24-h serum cortisol or 24-h urine cortisol
excretion by 20 and 17 %, respectively.
Acknowledgments The author meets the criteria for authorship set
forth by the International Committee for Medical Journal Editors, was
involved in the preparation of the article and approved the final draft
for submission. The author thanks the subjects and staff who partic-
ipated in each of the studies. Bioanalytical support for the fluticasone
furoate analyses was provided by Worldwide Bioanalysis, Ware,
Herts, UK. Editorial support in the form of copyediting and graphic
services was provided by Ian Grieve at Gardiner-Caldwell Commu-
nications and was funded by GlaxoSmithKline. All the studies used in
this analysis were funded by GlaxoSmithKline.
Statement of interest A.A. is employed by and holds stock in
GlaxoSmithKline.
Role of the Funding Source This study was funded by Glaxo-
SmithKline and the sponsor was involved in the design and conduct
of the studies, collection of data, and analysis and interpretation of the
data. The author had access to all of the data, was involved in every
stage of the preparation of the article, performed the statistical anal-
ysis, and approved the final version. The sponsor did not place any
restriction on authors about the statements made in the final article.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and the source are credited.
References
1. Lo¨tvall J, Bakke P, Bjermer L, et al. Safety and efficacy of flu-
ticasone furoate/vilanterol trifenatate (FF/VI) in COPD patients.
Eur Respir J 2010;24:1013s.
2. Kempsford R, Allen A, Bareille P, et al. The safety, tolerability,
pharmacodynamics and pharmacokinetics of inhaled fluticasone
furoate (FF) and vilanterol (VI) are unaffected by administration
in combination. Eur Respir J. 2011;38(Suppl. 55):138s.
3. Lo¨tvall J, Bakke PS, Bjermer L, et al. Efficacy and safety of
4 weeks’ treatment with combined fluticasone furoate/vilanterol
in a single inhaler given once daily in COPD: a placebo-con-
trolled randomised trial. BMJ Open. 2012;2:e000370.
4. Busse WW, O’Byrne PM, Bleecker ER, et al. Safety and toler-
ability of the novel inhaled corticosteroid (ICS) fluticasone
furoate (FF) in combination with the long-acting beta2 agonist
(LABA) vilanterol (VI) administered once daily (OD) in patients
with asthma. Eur Respir J. 2012;40(Suppl. 56):P2092.
5. Boscia JA, Pudi KK, Zvarich MT, et al. Effect of fluticasone
furoate (FF)/vilanterol (VI) administered once daily on 24 h
pulmonary function in patients with COPD: a randomized, three-
way, incomplete block, cross-over study. Am J Resp Crit Care
Med. 2012;185(Meeting abstracts):A2939.
6. Agusti A, De Backer W, De Teresa L, et al. Efficacy of combi-
nation fluticasone furoate/vilanterol (FF/VI) and salmeterol/flu-
ticasone propionate (SFC) over 12 weeks in patients with COPD.
Eur Respir J. 2012;40(Suppl. 56):P2889.
7. Bleecker ER, Lo¨tvall J, O’Bryne PM, et al. Efficacy of flutica-
sone furoate (FF) as a monotherapy and in combination with
vilanterol (VI) over 12 weeks in patients with persistent asthma.
Eur Respir J. 2012;40(Suppl. 56):P2091.
8. O’Byrne PM, Bleecker ER, Bateman ED, et al. Efficacy and
safety of fluticasone furoate (FF)/vilanterol (VI) once daily (OD)
for 24 weeks in persistent asthma. Eur Respir J. 2012;40(Suppl.
56):P1794.
9. Lipworth BJ, Seckl JR. Measures for detecting systemic bioac-
tivity with inhaled and intranasal corticosteroids. Thorax.
1997;52:476–82.
10. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid
therapy: a systemic review and meta-analysis. Arch Intern Med.
1999;159:941–55.
11. Bernstein DI, Allen DB. Evaluation of tests of hypothalamic–
pituitary–adrenal axis function used to measure effects of inhaled
corticosteroids. Ann Allergy Asthma Immunol. 2007;98:118–27.
12. Masoli M, Weatherall M, Holt S, et al. Inhaled fluticasone pro-
pionate and adrenal effects in adult asthma: systematic review
and meta-analysis. Eur Respir J. 2006;28:960–7.
13. Clark DJ, Grove A, Cargill RI, et al. Comparative adrenal sup-
pression with inhaled budesonide and fluticasone propionate in
adult asthmatic patients. Thorax. 1996;51:262–6.
14. Bruni FM, De Luca G, Venturoli V, et al. Intranasal corticoste-
roids and adrenal suppression. NeuroImmunoModulation.
2009;16:353–62.
15. Crowley S. Inhaled glucocorticoids and adrenal function: an
update. Paediatr Respir Rev. 2003;4:153–61.
16. Bleecker ER, Bateman ED, Busse WW, et al. Consistently
favorable safety profile of fluticasone furoate (FF), a once-daily
(OD) inhaled corticosteroid (ICS), across a range of treatment
steps in patients with uncontrolled asthma. AJRCCM. 2011;183:
A1300 (Abstract).
17. Busse WW, Bleecker ER, Bateman ED, et al. Fluticasone furoate
demonstrates efficacy in patients with asthma symptomatic on
medium doses of inhaled corticosteroid therapy: an 8-week,
randomised, placebo-controlled trial. Thorax. 2012;67:35–41.
18. Beal SL, Sheiner LB. NONMEM users guides, Version 5.
NONMEM Project Group, University of California, San Fran-
cisco. 1996.
19. Jonsson EN, Karlsson MO. Xpose—an S-PLUS based population
pharmacokinetic/pharmacodynamic model building aid for
NONMEM. Comput Methods Programs Biomed. 1999;58:51–64.
20. Post TM, Freijer JI, Ploeger BA, et al. Extensions to the visual
predictive check to facilitate model performance evaluation.
J Pharmacokinet Pharmacodyn. 2008;35:185–202.
Fluticasone Furoate and Cortisol Suppression 895
21. Juselius RE, Kenny FM. Urinary free cortisol excretion during
growth and aging: correlation with cortisol production rate and
17-hydroxycorticosteroid excretion. Metabolism. 1974;23:847–52.
22. Mackie AE, Bye A. The relationship between systemic exposure
to fluticasone propionate and cortisol reduction in healthy male
volunteers. Clin Pharmacokinet. 2000;39(Suppl. 1):47–54.
23. Daley-Yates PT, Tournant J, Kunka RL. Comparison of the
systemic availability of fluticasone propionate in healthy volun-
teers and patients with asthma. Clin Pharmacokinet. 2000;39
(Suppl. 1):39–45.
896 A. Allen
